Nationwide Children's Hospital

Neuroscience

A multicenter look at gene therapy for spinal muscular atrophy

In May 2019, the U.S. Food and Drug Administration (FDA) approved a gene replacement therapy for the inherited, progressive neuromuscular disease 5q-linked spinal muscular atrophy (SMA). Approval included all children with ...

page 5 from 32